India, Oct. 2 -- The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiovascular care, immunology and metabolic health.
Let us unpack the specifics.
Regulatory Approvals
FDA Approves Edwards' First Adjustable Pulmonary Valve for Children
Edwards LifeScineces (EW) received FDA approval for the AUTUS Size-Adjustable Valve for pediatric patients with congenital heart disease requiring pulmonary valve replacement. The approval was supported by pivotal study data showing 100% freedom from device-related complications at 30 days and n...